Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results

Key Points

• PD-L1-positive status is linked to more favorable long-term outcomes in early-stage and metastatic triple-negative breast cancer.
• In the study, findings reveal that a significant portion of cases exhibit de novo metastatic triple-negative breast cancer.
• This analysis engages with over 2000 patients, indicating potential enrolment bias and geographic diagnosis variations.
• Further understanding of tumour-intrinsic characteristics and host immune responses is crucial for advancing treatment strategies.